Most benefit of RSLV-132 seen in patients with more active SLE
RSLV-132 failed to lessen damage caused by skin lesions in SLE in a trial, but tended to ease symptoms in patients with more active disease.| Lupus News Today
RSLV-132 failed to lessen damage caused by skin lesions in SLE in a trial, but tended to ease symptoms in patients with more active disease.| Lupus News Today
The FDA has updated the prescribing label for Lupkynis to show that it continues to safely preserve kidney function for up to three years.| Lupus News Today
Columnist Candace Semien describes the sort of personal surveillance she wants in case she has a lupus flare or other emergency.| Lupus News Today
Antiphospholipid antibodies (phospholipid are fat molecules) were seen to increase the likelihood of heart disease or the like with SLE.| Lupus News Today
Professor Tianfu Wu is developing a spleen-specific drug delivery system to suppress lupus-causing immune cells and reduce side effects.| Lupus News Today
Author archive page for Margarida Maia.| Lupus News Today
The FDA has granted fast track status to ADI-001, Adicet Bio’s CAR T-cell therapy for treatment-resistant systemic lupus erythematosus (SLE).| Lupus News Today
The first patient has been treated in a Phase 1 clinical trial testing CAR T-cell therapy CC-97540 in people with severe, refractory lupus.| Lupus News Today
